<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04390984</url>
  </required_header>
  <id_info>
    <org_study_id>HR-APTN-DDI-004</org_study_id>
    <nct_id>NCT04390984</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients</brief_title>
  <official_title>A Multi-center, Open-label, Fixed-sequence Study of Effect of Gefitinib on the Pharmacokinetics of Apatinib Mesylate in Non-squamous, Non-small-cell Lung Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study was to assess the effect of gefitinib on the&#xD;
      pharmacokinetics of apatinib mesylate in lung cancer patients.&#xD;
&#xD;
      The secondary objective of the study was to assess the pharmacokinetics of gefitinib, and to&#xD;
      assess the safety of apatinib mesylate and gefitinib administered in lung cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All the subjects will administrated with apatinib and gefitinib following the same sequence to assess the effect of gefitinib on the pharmacokinetics of apatinib in NSCLC patients</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Maximum Observed Plasma Concentration for apatinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-τ</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Area Under the Concentration-time Curve From Zero (Pre-dose) to 24 hours</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administrated with 500mg apatinib on day 1 and day 12-15, and administrated with gefitinib on day 4-15.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib Mesylate, Gefitinib</intervention_name>
    <description>Subjects will be administrated with 500mg apatinib on day 1 and day 12-15, and administrated with gefitinib on day 4-15.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18-75 years of age.&#xD;
&#xD;
          2. ECOG performance status: level 0~1;&#xD;
&#xD;
          3. Anticipated life expectancy ≥ 12 weeks;&#xD;
&#xD;
          4. Lung cancer patients;&#xD;
&#xD;
          5. Major organs in good function;&#xD;
&#xD;
          6. Agree to take approved method of contraception during the clinical trail and 8 weeks&#xD;
             after the last dose of apatinib. Female subject should be negative in the pregnancy&#xD;
             test;&#xD;
&#xD;
          7. Able to comprehend and willing to sign an informed consent form (ICF)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of drug allergy, or allergic to apatinib or gefitinib or ingredients;&#xD;
&#xD;
          2. Squamous cancer, small-cell lung cancer;&#xD;
&#xD;
          3. Symptomatic central nervous system (CNS) metastases&#xD;
&#xD;
          4. Hypertension and couldn't be controlled with medicine;&#xD;
&#xD;
          5. Coagulation disorders;&#xD;
&#xD;
          6. Clinical significant bleeding in 3 months prior dosing;&#xD;
&#xD;
          7. Had surgery in four weeks prior dosing;&#xD;
&#xD;
          8. Disease that affect drug absorption, such as inability to swallow, chronic diarrhea&#xD;
             and intestinal obstruction;&#xD;
&#xD;
          9. Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess in 6 months&#xD;
             prior dosing;&#xD;
&#xD;
         10. Urine protein ≥++, and urine protein ≥1.0g in 24 hours;&#xD;
&#xD;
         11. Active infection and need antimicrobial treatments;&#xD;
&#xD;
         12. History of psychiatric substance abuse;&#xD;
&#xD;
         13. Take any clinical trial drugs within four weeks prior dosing;&#xD;
&#xD;
         14. Take any drugs that have effect on gastric acid and metabolic enzyme CYP 3A and&#xD;
             CYP2D6;&#xD;
&#xD;
         15. Combined with other viral infections (anti-HCV, anti-HIV positive, HBsAg positive) or&#xD;
             combined with syphilis infection;&#xD;
&#xD;
         16. Addicted to alcohol and tobacco;&#xD;
&#xD;
         17. Take grapefruit or grapefruit product, drinks containing caffeine, xanthine and&#xD;
             alcohol in 48 hours prior dosing;&#xD;
&#xD;
         18. The investigator believes that the subjects are not eligible to participate in this&#xD;
             trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuya Wang, Ph.D</last_name>
    <phone>13918749176</phone>
    <email>wangyuya@hrglobe.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-Sen Univercity Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zhang</last_name>
      <phone>86-020-87343458</phone>
      <email>Zhangli6@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 13, 2020</study_first_submitted>
  <study_first_submitted_qc>May 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2020</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

